BioSpace News Archive

Axena Health, Inc. announced the results of a one-year longitudinal follow up to its pivotal randomized controlled superiority trial of the Leva® Pelvic Health System as a treatment for urinary incontinence in women.

Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it has received final approval from the U.S. Food and Drug Administration (“FDA”) for its Abbreviated New Drug Application (“ANDA”) for Acetaminophen and Ibuprofen Tablets, 250 mg/125 mg, the store brand over-the-counter (“OTC”) equivalent of Advil® Dual Action Tablets 250 mg/125 mg.

Positron Corporation is pleased to announce that it has executed a Clinical Study/Research Agreement with Ochsner Clinic Foundation and Dr. Bober, Director of Molecular Imaging and Nuclear Cardiology at Ochsner Health, for the clinical study of its new PET-CT imaging device, the Affinity™ PET-CT 4D.

BRENUS PHARMA, a French private biotechnology start-up specialized in the development of first in class tumor-antigen focused immunotherapies announced the recruitment of its Strategic Committee composed by renowned pharma-industry and biotech executives.

iTolerance, Inc. (“iTolerance” or the “Company”), an early-stage regenerative medicine company developing technologies to enable tissue, organoid or cell therapy without the need for life-long immunosuppression, today announced it has completed a Pre-Investigational New Drug Application (“pre-IND”) meeting with the U.S. Food and Drug Administration (“FDA”) to discuss the development of the Company’s iTOL-100 immunomodulatory technology.

Providing faster, higher quality results with enterprise digital pathology

The Well Told Company Inc. (TSXV: WLCO) (FSE: 7HO) (“Well Told” or the “Company”), the female-founded wellness company that offers plant-based supplements, remedies, and other functional wellness products, announces details of the debt conversion previously announced on February 17, 2023.

Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced the appointment of five new members to its Gene Therapy Scientific Advisory Board (SAB).

Insmed Incorporated today announced that management will present at the following investor conferences.

Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced that it has granted inducement stock options to purchase an aggregate of 7,360 shares of its common stock to two new employees.